Alberto Aimo

List of Publications by Year
in descending order

151 papers	3,530 citations	185998 28 h-index	174990 52 g-index
154 all docs	154 docs citations	154 times ranked	4150 citing authors

#	Article	IF	Citations
1	Predictors of adverse prognosis in COVIDâ€19: A systematic review and metaâ€analysis. European Journal of Clinical Investigation, 2020, 50, e13362.	1.7	275
2	Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure. Circulation, 2018, 137, 286-297.	1.6	157
3	Oxidative stress and inflammation in the evolution of heart failure: From pathophysiology to therapeutic strategies. European Journal of Preventive Cardiology, 2020, 27, 494-510.	0.8	142
4	Multiparametric Echocardiography Scores for the Diagnosis of CardiacÂAmyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 909-920.	2.3	136
5	Biomarkers for the diagnosis and management of heart failure. Heart Failure Reviews, 2022, 27, 625-643.	1.7	135
6	Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure. JACC: Heart Failure, 2017, 5, 280-286.	1.9	127
7	COVID-19 and myocarditis: a systematic review and overview of current challenges. Heart Failure Reviews, 2022, 27, 251-261.	1.7	127
8	sST2 Predicts Outcome in ChronicÂHeartÂFailure Beyond NTâ€'proBNP and High-Sensitivity Troponin T. Journal of the American College of Cardiology, 2018, 72, 2309-2320.	1.2	126
9	Treatment of cardiac transthyretin amyloidosis: an update. European Heart Journal, 2019, 40, 3699-3706.	1.0	121
10	Imaging, Biomarker, and Clinical Predictors of Cardiac Remodeling inÂHeartÂFailure With ReducedÂEjectionÂFraction. JACC: Heart Failure, 2019, 7, 782-794.	1.9	113
11	Clinical and Prognostic Significance of sST2 in HeartÂFailure. Journal of the American College of Cardiology, 2019, 74, 2193-2203.	1.2	110
12	Meta-Analysis of Soluble Suppression ofÂTumorigenicity-2 and Prognosis in Acute Heart Failure. JACC: Heart Failure, 2017, 5, 287-296.	1.9	104
13	Targeting Cyclic Guanosine Monophosphate to Treat HeartÂFailure. Journal of the American College of Cardiology, 2020, 76, 1795-1807.	1.2	71
14	RNA-targeting and gene editing therapies for transthyretin amyloidosis. Nature Reviews Cardiology, 2022, 19, 655-667.	6.1	64
15	Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction. International Journal of Cardiology, 2019, 296, 91-97.	0.8	60
16	Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings. European Journal of Preventive Cardiology, 2020, 27, 1806-1815.	0.8	60
17	Pirfenidone is a cardioprotective drug: Mechanisms of action and preclinical evidence. Pharmacological Research, 2020, 155, 104694.	3.1	52
18	Redefining the epidemiology of cardiac amyloidosis. A systematic review and metaâ€analysis of screening studies. European Journal of Heart Failure, 2022, 24, 2342-2351.	2.9	51

#	Article	IF	Citations
19	Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets. Heart Failure Reviews, 2021, 26, 881-890.	1.7	43
20	Sex-related differences in chronic heart failure. International Journal of Cardiology, 2018, 255, 145-151.	0.8	41
21	The IL-33/ST2 pathway, inflammation and atherosclerosis: Trigger and target?. International Journal of Cardiology, 2018, 267, 188-192.	0.8	40
22	Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis. Cardiovascular Drugs and Therapy, 2021, 35, 1067-1076.	1.3	40
23	Late gadolinium enhancement as a predictor of functional recovery, need for defibrillator implantation and prognosis in non-ischemic dilated cardiomyopathy. International Journal of Cardiology, 2018, 250, 195-200.	0.8	37
24	Critical Comparison of Documents FromÂScientific Societies on CardiacÂAmyloidosis. Journal of the American College of Cardiology, 2022, 79, 1288-1303.	1.2	35
25	Safety and Tolerability of Neurohormonal Antagonism in Cardiac Amyloidosis. European Journal of Internal Medicine, 2020, 80, 66-72.	1.0	34
26	Amyloid Deposits and Fibrosis on Left Ventricular Endomyocardial Biopsy Correlate With Extracellular Volume in Cardiac Amyloidosis. Journal of the American Heart Association, 2021, 10, e020358.	1.6	34
27	Deep learning to diagnose cardiac amyloidosis from cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2020, 22, 84.	1.6	33
28	Use of biomarkers to diagnose and manage cardiac amyloidosis. European Journal of Heart Failure, 2021, 23, 217-230.	2.9	33
29	High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure. International Journal of Cardiology, 2019, 277, 166-172.	0.8	32
30	Cardioprotection by remote ischemic conditioning: Mechanisms and clinical evidences. World Journal of Cardiology, 2015, 7, 621.	0.5	31
31	Therapies for cardiac light chain amyloidosis: An update. International Journal of Cardiology, 2018, 271, 152-160.	0.8	31
32	Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure. JACC: Heart Failure, 2017, 5, 735-742.	1.9	30
33	The ergoreflex: how the skeletal muscle modulates ventilation and cardiovascular function in health and disease. European Journal of Heart Failure, 2021, 23, 1458-1467.	2.9	29
34	Cardiac remodellingÂâ€“ÂPart 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 927-943.	2.9	29
35	Revisiting the obesity paradox in heart failure: Per cent body fat as predictor of biomarkers and outcome. European Journal of Preventive Cardiology, 2019, 26, 1751-1759.	0.8	28
36	Cardiac troponins as biomarkers for cardiac disease. Biomarkers in Medicine, 2019, 13, 325-330.	0.6	28

#	Article	IF	Citations
37	NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure. International Journal of Cardiology, 2018, 271, 324-330.	0.8	27
38	Cardiovascular disease and COVID-19: les liaisons dangereuses. European Journal of Preventive Cardiology, 2020, 27, 1017-1025.	0.8	27
39	Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than Nâ€terminal proâ€Bâ€type natriuretic peptide and highâ€sensitivity troponin T. European Journal of Heart Failure, 2020, 22, 2078-2088.	2.9	26
40	Admission high-sensitivity troponin T and NT-proBNP for outcome prediction in acute heart failure. International Journal of Cardiology, 2019, 293, 137-142.	0.8	24
41	Effect of lowâ€dose colchicine in acute and chronic coronary syndromes: A systematic review and metaâ€analysis. European Journal of Clinical Investigation, 2021, 51, e13464.	1.7	24
42	A simple echocardiographic score to rule out cardiac amyloidosis. European Journal of Clinical Investigation, 2021, 51, e13449.	1.7	24
43	Integration of imaging and circulating biomarkers in heart failure: a consensus document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 1577-1596.	2.9	23
44	Procalcitonin, white blood cell count and C-reactive protein as predictors of S. aureus infection and mortality in infective endocarditis. International Journal of Cardiology, 2020, 301, 190-194.	0.8	22
45	Current and emerging drug targets in heart failure treatment. Heart Failure Reviews, 2022, 27, 1119-1136.	1.7	22
46	Cardiac remodellingÂâ€“ÂPart 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 944-958.	2.9	22
47	Body mass index and outcomes in ischaemic versus non-ischaemic heart failure across the spectrum of ejection fraction. European Journal of Preventive Cardiology, 2020, , 204748732092761.	0.8	21
48	The relationship between blood pressure and risk of atrial fibrillation: a Mendelian randomization study. European Journal of Preventive Cardiology, 2022, 29, 1494-1500.	0.8	20
49	Vericiguat for Heart Failure with Reduced Ejection Fraction. Current Cardiology Reports, 2021, 23, 144.	1.3	19
50	Pirfenidone as a novel cardiac protective treatment. Heart Failure Reviews, 2022, 27, 525-532.	1.7	19
51	Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond. Cardiac Failure Review, 2022, 8, e12.	1.2	19
52	Autonomic, functional, skeletal muscle, and cardiac abnormalities are associated with increased ergoreflex sensitivity in mitochondrial disease. European Journal of Heart Failure, 2017, 19, 1701-1709.	2.9	18
53	Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis. European Heart Journal Cardiovascular Imaging, 2022, 24, 130-141.	0.5	18
54	Headâ€toâ€head comparison between recommendations by the <scp>ESC</scp> and <scp>ACC</scp>/<scp>AHA</scp>/<scp>HFSA</scp> heart failure guidelines. European Journal of Heart Failure, 2022, 24, 916-926.	2.9	18

#	Article	IF	Citations
55	Preâ€treatment highâ€sensitivity troponin T for the shortâ€term prediction of cardiac outcomes in patients on immune checkpoint inhibitors. European Journal of Clinical Investigation, 2021, 51, e13400.	1.7	17
56	Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis. European Journal of Clinical Investigation, 2021, 51, e13598.	1.7	16
57	Molecular Autopsy of Sudden Cardiac Death in the Genomics Era. Diagnostics, 2021, 11, 1378.	1.3	16
58	Echocardiography versus computed tomography and cardiac magnetic resonance for the detection of left heart thrombosis: a systematic review and meta-analysis. Clinical Research in Cardiology, 2021, 110, 1697-1703.	1.5	15
59	High-sensitivity troponins for outcome prediction in the general population: a systematic review and meta-analysis. European Journal of Internal Medicine, 2022, 98, 61-68.	1.0	15
60	Circulating levels and prognostic cutâ€offs of sST2, hsâ€cTnT, and NTâ€proBNP in women vs. men with chronic heart failure. ESC Heart Failure, 2022, 9, 2084-2095.	1.4	15
61	The extent and location of late gadolinium enhancement predict defibrillator shock and cardiac mortality in patients with non-ischaemic dilated cardiomyopathy. International Journal of Cardiology, 2020, 307, 180-186.	0.8	14
62	Cardiovascular magnetic resonance for the diagnosis and management of heart failure with preserved ejection fraction. Heart Failure Reviews, 2022, 27, 191-205.	1.7	13
63	N-terminal fraction of pro-B-type natriuretic peptide versus clinical risk scores for prognostic stratification in chronic systolic heart failure. European Journal of Preventive Cardiology, 2018, 25, 889-895.	0.8	12
64	Management of complications of cardiac amyloidosis: 10 questions and answers. European Journal of Preventive Cardiology, 2021, 28, 1000-1005.	0.8	12
65	Healthy hearts at hectic pace: From daily life stress to abnormal cardiomyocyte function and arrhythmias. European Journal of Preventive Cardiology, 2018, 25, 1419-1430.	0.8	11
66	Left ventricular ejection fraction for risk stratification in chronic systolic heart failure. International Journal of Cardiology, 2018, 273, 136-140.	0.8	11
67	Cardiac magnetic resonance in patients with muscular dystrophies. European Journal of Preventive Cardiology, 2021, 28, 1526-1535.	0.8	11
68	Prognostic value of reverse remodelling criteria in heart failure with reduced or midâ€range ejection fraction. ESC Heart Failure, 2021, 8, 3014-3025.	1.4	11
69	Indications of beta-adrenoceptor blockers in Takotsubo syndrome and theoretical reasons to prefer agents with vasodilating activity. International Journal of Cardiology, 2021, 333, 45-50.	0.8	11
70	Sex-related differences in ventricular remodeling after myocardial infarction. International Journal of Cardiology, 2021, 339, 62-69.	0.8	11
71	Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis. Heart Failure Reviews, 2022, 27, 2187-2200.	1.7	11
72	Colchicine for the treatment of coronary artery disease. Trends in Cardiovascular Medicine, 2021, 31, 497-504.	2.3	10

#	Article	IF	Citations
73	Cardiac sympathetic denervation in wild-type transthyretin amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 237-243.	1.4	10
74	The Barthel Index in elderly acute heart failure patients. Frailty matters. International Journal of Cardiology, 2018, 254, 240-241.	0.8	9
75	Diphosphonate single-photon emission computed tomography in cardiac transthyretin amyloidosis. International Journal of Cardiology, 2020, 307, 187-192.	0.8	9
76	Subclinical cardiac damage in cancer patients before chemotherapy. Heart Failure Reviews, 2022, 27, 1091-1104.	1.7	9
77	Evaluation of pathophysiological relationships between renin-angiotensin and ACE-ACE2 systems in cardiovascular disorders: from theory to routine clinical practice in patients with heart failure. Critical Reviews in Clinical Laboratory Sciences, 2021, 58, 530-545.	2.7	9
78	Triglyceride-glucose index predicts outcome in patients with chronic coronary syndrome independently of other risk factors and myocardial ischaemia. European Heart Journal Open, 2021, 1, .	0.9	9
79	The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction. Heart Failure Reviews, 2021, , 1.	1.7	9
80	Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 252-258.	1.4	9
81	Longitudinal strain in the management of cardiac AL amyloidosis: do we need it?. European Heart Journal, 2022, 43, 342-344.	1.0	9
82	sST2 for Outcome Prediction in AcuteÂHeartÂFailure. Journal of the American College of Cardiology, 2019, 74, 478-479.	1.2	7
83	Myocardial perfusion years after radiation therapy for left-sided breast cancer: Normal or abnormal? This is the question. Journal of Nuclear Cardiology, 2021, 28, 1933-1935.	1.4	7
84	The central role of invasive functional coronary assessment for patients with ischemic heart disease. International Journal of Cardiology, 2021, 331, 17-25.	0.8	7
85	Imaging predictors of incident heart failure: a systematic review and meta-analysis. Journal of Cardiovascular Medicine, 2021, 22, 378-387.	0.6	7
86	Neurohormonal modulation for treatment of cardiac involvement in dystrophinopathies and mitochondrial disease. European Journal of Preventive Cardiology, 2017, 24, 1718-1724.	0.8	6
87	Wet is bad: Residual congestion predicts worse prognosis in acute heart failure. International Journal of Cardiology, 2018, 258, 201-202.	0.8	6
88	Quality of life and outcome in heart failure with preserved ejection fraction: When sex matters. International Journal of Cardiology, 2018, 267, 141-142.	0.8	6
89	Morphologies and prognostic significance of left ventricular volume/time curves with cardiac magnetic resonance in patients with non-ischaemic heart failure and left bundle branch block. International Journal of Cardiovascular Imaging, 2021, 37, 2245-2255.	0.7	6
90	Discharge FGF23 level predicts one year outcome in patients admitted with acute heart failure. International Journal of Cardiology, 2021, 336, 98-104.	0.8	6

#	Article	IF	Citations
91	Remote Ischemic Conditioning in Ischemic Stroke and Myocardial Infarction: Similarities and Differences. Frontiers in Neurology, 2021, 12, 716316.	1.1	6
92	Aspirin Therapy for Primary Prevention: The Case for Continuing Prescribing to Patients at High Cardiovascular Riskâ€"A Review. Thrombosis and Haemostasis, 2020, 120, 199-206.	1.8	5
93	The unbearable underreporting of comorbidities in heart failure clinical trials. European Journal of Heart Failure, 2020, 22, 1043-1044.	2.9	5
94	Cardiac magnetic resonance in patients with ARVC and family members: the potential role of native T1 mapping. International Journal of Cardiovascular Imaging, 2021, 37, 2037-2047.	0.7	5
95	Prognostic Benefit of New Drugs for HFrEF: A Systematic Review and Network Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 348.	1.0	5
96	Natriuretic Peptides and Troponins to Predict Cardiovascular Events in Patients Undergoing Major Non-Cardiac Surgery. International Journal of Environmental Research and Public Health, 2022, 19, 5182.	1.2	5
97	Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin. Heart Failure Reviews, 2022, , .	1.7	5
98	How to take arms against central apneas in heart failure. Expert Review of Cardiovascular Therapy, 2017, 15, 743-755.	0.6	4
99	Cardiac light-chain deposition disease relapsing in the transplanted heart. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 135-137.	1.4	4
100	Building medical knowledge from real world registries: The case of heart failure. IJC Heart and Vasculature, 2018, 19, 98-99.	0.6	4
101	Scared to Death. JACC: Case Reports, 2020, 2, 2400-2403.	0.3	4
102	The triglyceride/HDL cholesterol ratio and TyG index predict coronary atherosclerosis and outcome in the general population. European Journal of Preventive Cardiology, 2022, 29, e203-e204.	0.8	4
103	Aspirin for primary cardiovascular prevention: why the wonder drug should not be precipitously dismissed. Polish Archives of Internal Medicine, 2020, 130, 121-129.	0.3	4
104	Cardiac protection by pirfenidone after myocardial infarction: a bioinformatic analysis. Scientific Reports, 2022, 12, 4691.	1.6	4
105	Echocardiographic and Cardiac Magnetic Resonance Imaging-Derived Strains in Relation to Late Gadolinium Enhancement in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2022, 171, 132-139.	0.7	4
106	The heart after idarubicin overdose. Cardiac death in a patient with acute promyelocitic leukaemia. International Journal of Cardiology, 2016, 203, 997-999.	0.8	3
107	Rituximab as a novel treatment for heart failure: evidence from a case series. European Heart Journal - Case Reports, 2019, 3, 1-2.	0.3	3
108	Abdominal Fat Biopsy for the Diagnosis of Cardiac Amyloidosis. JACC: Case Reports, 2020, 2, 1182-1185.	0.3	3

#	Article	IF	Citations
109	Searching for diagnostic biomarkers of heart failure with preserved ejection fraction: methodological issues. European Journal of Heart Failure, 2020, 22, 1598-1599.	2.9	3
110	Safety and efficacy of levosimendan in patients with cardiac amyloidosis. European Journal of Internal Medicine, 2020, 80, 114-116.	1.0	3
111	Exercise intolerance in heart failure with preserved ejection fraction: A reappraisal of central mechanisms?. International Journal of Cardiology, 2018, 254, 248-249.	0.8	2
112	Natriuretic peptides. D'oÃ¹ venons-nous? Que sommes-nous? OÃ¹ allons-nous?. International Journal of Cardiology, 2018, 254, 256-257.	0.8	2
113	Low-Thrombogenicity Mechanical Heart Valves. Journal of the American College of Cardiology, 2018, 72, 1878-1879.	1.2	2
114	Daptomycin-based aminoglycoside-sparing therapy for streptococcal endocarditis: a retrospective multicenter study. Journal of Chemotherapy, 2021, 33, 435-439.	0.7	2
115	The pathophysiological and clinical relevance of combined measurement of natriuretic peptides and cardiac troponins for risk prediction of incident heart failure in communityâ€dwelling individuals. European Journal of Heart Failure, 2021, 23, 403-405.	2.9	2
116	Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient. JACC: Case Reports, 2021, 3, 450-454.	0.3	2
117	Overlapping Effects of miR-21 Inhibition and Drugs for Idiopathic Pulmonary Fibrosis: Rationale for Repurposing Nintedanib as a Novel Treatment for Ischemia/Reperfusion Injury. Journal of Cardiovascular Pharmacology, 2021, 77, 332-333.	0.8	2
118	Norepinephrine, plasma renin activity and cardiovascular mortality in systolic heart failure. Heart, 2021, 107, 989-995.	1.2	2
119	The influence of sex and body mass index on the association between soluble neprilysin and risk of heart failure hospitalizations. Scientific Reports, 2021, 11, 5940.	1.6	2
120	How much is it to mend a broken heart? Results from the US Nationwide Readmission Database. International Journal of Cardiology, 2021, 329, 150-151.	0.8	2
121	Urinary NGAL in acute heart failure revisited: the game is not over yet. International Journal of Cardiology, 2022, 357, 113-114.	0.8	2
122	Big gamma-glutamyltransferase is associated with epicardial fat volume and cardiovascular outcome in the general population. European Journal of Preventive Cardiology, 2022, 29, 1510-1518.	0.8	2
123	Are big data on myocardial infarction enough for small heart failure patients? Lessons from a national registry. International Journal of Cardiology, 2017, 248, 278-279.	0.8	1
124	Neurohormonal modulation for treatment of cardiac involvement in dystrophinopathies and mitochondrial disease. European Journal of Preventive Cardiology, 2017, 24, 1727-1728.	0.8	1
125	Noncardiovascular death after acute heart failure. Do not lose the war while fighting for the failing heart. International Journal of Cardiology, 2018, 250, 231-232.	0.8	1
126	Heart, kidney and FGF23: Les liaisons dangereuses. International Journal of Cardiology, 2018, 253, 120-121.	0.8	1

#	Article	IF	Citations
127	What Is Hidden Behind Inferior NegativeÂT Waves. JACC: Case Reports, 2019, 1, 657-662.	0.3	1
128	Integrated Imaging to Investigate Low-Flow Alarms of LeftÂVentricularÂAssist Devices. JACC: Case Reports, 2020, 2, 1457-1460.	0.3	1
129	Intracoronary Delivery of Mitochondria to Prevent Ischemiaâ€“Reperfusion Injury. JACC Basic To Translational Science, 2020, 5, 208.	1.9	1
130	Effects of vericiguat in heart failure with reduced ejection fraction: do not forget <scp>sST2</scp>. Letter regarding the article â€˜Baseline features of the VICTORIA (Vericiguat Global Study in Subjects) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 1934-1935.	2.9	1
131	The Relativity of Reference Values for Myocardial Perfusion Imaging. JACC: Cardiovascular Imaging, 2021, 14, 666-668.	2.3	1
132	Tafamidis is entering the clinical arena for the treatment of transthyretinâ€related cardiomyopathy: certainties and unmet needs. European Journal of Heart Failure, 2021, 23, 286-289.	2.9	1
133	Exercise tolerance and quality of life in patients with known or suspected coronary artery disease. Quality of Life Research, 2021, 30, 2541-2550.	1.5	1
134	Cocaine and methamphetamine use and hospitalization for acute heart failure: Epidemiological evidence from a nationwide dataset. International Journal of Cardiology, 2021, 333, 141-142.	0.8	1
135	Response to the comment by Dr Yarlas. European Journal of Clinical Investigation, 2021, 51, e13652.	1.7	1
136	The Left Ventricular Mass-to-Strain Ratio. JACC: Cardiovascular Imaging, 2021, 14, 1877-1878.	2.3	1
137	Thyroid, Heart Failure, and Neuroendocrine Activation. , 2020, , 301-309.		1
138	Magnetic Resonance to Diagnose CardiacÂAmyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 1293-1294.	2.3	1
139	Is targeting cyclic guanosine monophosphate by vericiguat effective to treat ischaemic heart failure with reduced ejection fraction? Yes, it is. European Journal of Heart Failure, 2022, 24, 791-793.	2.9	1
140	Do we need to EVALUATE multiple biomarkers and/or the same biomarkers multiple times in patients with heart failure?. European Journal of Heart Failure, 2022, 24, 1209-1211.	2.9	1
141	A mechanistic look at sacubitril/valsartan action. Unravelling magician's secrets. International Journal of Cardiology, 2018, 258, 203-204.	0.8	0
142	Is fat good for arrhythmias in ischemic heart failure? Another face of the obesity paradox. International Journal of Cardiology, 2018, 265, 169-170.	0.8	0
143	Relative hypochromia in acute heart failure to predict outcome and guide treatment: Ready for prime time?. International Journal of Cardiology, 2019, 286, 111-112.	0.8	0
144	Letter by Aimo et al Regarding Article, â€œDevelopment and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathiesâ€• Circulation, 2019, 140, e816-e817.	1.6	0

#	Article	IF	Citations
145	Scoring frailty in patients hospitalized for heart failure: Impact on prognosis (and decision making,) Tj ETQq1 1 0.784314 rgBT /Overlock	0.8	0
146	Evaluating biomarkers as predictors of cancer therapy cardiotoxicity: all you need is a metaâ€analysis?. Letter regarding the article â€˜Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a metaâ€analysis.â€™. European Journal of Heart Failure, 2020, 22, 1284-1285.	2.9	0
147	Longitudinal changes in cardiac biomarkers and outcome in heart failure: Sex-related differences. International Journal of Cardiology, 2021, 336, 84-85.	0.8	0
148	Digoxin use in patients with cardiovascular diseases: An old remedy for future medicine?. International Journal of Cardiology, 2021, 339, 106-107.	0.8	0
149	Heart diseases (autonomic dysfunctions)â€”Myocardial innervation imaging: 123I-MIBG planar scintigraphy and SPECT. , 2021, , .		0
150	Plasma acylcarnitine, risk for heart failure or atrial fibrillation, and effects of the Mediterranean diet or obesity. Revista Espanola De Cardiologia (English Ed), 2022, , .	0.4	0
151	Stroke in ATTR cardiac amyloidosis: Does only rhythm matter?. International Journal of Cardiology, 2022, , .	0.8	0